|View printer-friendly version|
Since co-founding KindredBio in 2012, Ms. Bevers has assumed increasing levels of responsibility and has been instrumental in growing KindredBio into one of the world's leading veterinary biopharmaceutical companies. In her expanded role as President, Ms. Bevers will be responsible for all operational functions. She will retain her title as COO and continue to oversee the commercial organization, including the launch of KindredBio's first product, Mirataz® (mirtazapine transdermal ointment).
"Denise is a remarkably talented leader and it is a pleasure to announce her well-deserved promotion and election to our Board. As KindredBio's Co-Founder, she has been critical in our successes, including our recent transition to a commercial-stage company, and in our mission to transform veterinary medicine. I would like to personally thank her for her partnership and tireless dedication as we steer KindredBio toward even greater heights," said
Ms. Bevers is an experienced pharmaceutical executive with a distinguished career in clinical operations, medical affairs, and scientific communications. With over 20 years of pharmaceutical and research experience, she has successfully managed dozens of product launches and development programs from Phase I through Phase IV. Ms. Bevers previously held leadership positions at
"I am honored to be appointed to the Board and promoted to President, and I look forward to furthering KindredBio's mission of bringing the best of the best human medications to pets," said Ms. Bevers. "I am incredibly energized to continue to advance our deep pipeline of novel drugs and biologics in development, and lead KindredBio to its next phase of growth."
Important Safety Information
Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients or in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves to apply and wash hands after. Avoid contact with treated cat for 2 hours following application. The most common adverse reactions include application site reactions, behavioral abnormalities (vocalization and hyperactivity) and vomiting. Please see the full Prescribing Information.
About Kindred Biosciences
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our expectations about the trials, regulatory approval, manufacturing, distribution and commercialization of our current and future product candidates, and statements regarding our anticipated revenues, expenses, margins, profits and use of cash.
These forward-looking statements are based on our current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future results expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: our limited operating history and expectations of losses for the foreseeable future; the absence of significant revenue from our product candidates for the foreseeable future; our potential inability to obtain any necessary additional financing; our substantial dependence on the success of our lead product candidates, which may not be successfully commercialized even if they are approved for marketing; the effect of competition; our potential inability to obtain regulatory approval for our existing or future product candidates; our dependence on third parties to conduct some of our development activities; our dependence upon third-party manufacturers for supplies of our product candidates; uncertainties regarding the outcomes of trials regarding our product candidates; our potential failure to attract and retain senior management and key scientific personnel; uncertainty about our ability to develop a satisfactory sales organization; our significant costs of operating as a public company; our potential inability to obtain patent protection and other intellectual property protection for our product candidates; potential claims by third parties alleging our infringement of their patents and other intellectual property rights; our potential failure to comply with regulatory requirements, which are subject to change on an ongoing basis; the potential volatility of our stock price; and the significant control over our business by our principal stockholders and management.
For a further description of these risks and other risks that we face, please see the risk factors described in our filings with the
For investor inquiries:
For media inquiries:
View original content to download multimedia:http://www.prnewswire.com/news-releases/kindred-biosciences-elects-denise-bevers-to-its-board-of-directors-and-promotes-her-to-president-300735721.html